Citadel Advisors
ARQT icon

Citadel Advisors’s Arcutis Biotherapeutics ARQT Stock Holding History

Citadel Advisors’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$605K Sell
25,700
-8,200
-24% -$209K ﹤0.01% 8829
2025
Q4 		$984K Buy
33,900
+6,800
+25% +$174K ﹤0.01% 7425
2025
Q3 		$511K Sell
27,100
-15,300
-36% -$241K ﹤0.01% 9077
2025
Q2 		$594K Buy
42,400
+11,800
+39% +$165K ﹤0.01% 8230
2025
Q1 		$479K Buy
30,600
+1,900
+7% +$26.8K ﹤0.01% 8572
2024
Q4 		$400K Sell
28,700
-4,100
-13% -$44.9K ﹤0.01% 9051
2024
Q3 		$305K Buy
32,800
+12,000
+58% +$118K ﹤0.01% 9301
2024
Q2 		$193K Sell
20,800
-115,300
-85% -$1.04M ﹤0.01% 9989
2024
Q1 		$1.35M Buy
136,100
+83,400
+158% +$622K ﹤0.01% 6316
2023
Q4 		$170K Buy
52,700
+28,100
+114% +$76.4K ﹤0.01% 10197
2023
Q3 		$131K Buy
24,600
+4,300
+21% +$36.6K ﹤0.01% 10557
2023
Q2 		$193K Buy
20,300
+11,500
+131% +$128K ﹤0.01% 9947
2023
Q1 		$96.8K Sell
8,800
-300
-3% -$4.34K ﹤0.01% 11313
2022
Q4 		$135K Buy
+9,100
New +$159K ﹤0.01% 10775
2022
Q1 		– Sell
-14,600
Closed -$303K – 13525
2021
Q4 		$303K Buy
14,600
+3,300
+29% +$65.7K ﹤0.01% 10894
2021
Q3 		$270K Buy
11,300
+2,600
+30% +$59.3K ﹤0.01% 11287
2021
Q2 		$237K Buy
+8,700
New +$245K ﹤0.01% 11797

Other funds holding ARQT

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citadel Advisors's ARQT Position: Q1 2026 in Review

Citadel Advisors reduced its Arcutis Biotherapeutics (ARQT) stake by 90% in Q1 2026, selling an estimated $3.56M and leaving 15,606 shares worth $368K. The position accounts for ﹤0.01% of the portfolio, ranked #10004.

Citadel Advisors first reported a position in ARQT in Q1 2020 and has held it in 24 quarters since. The position peaked at $28.2M in Q3 2024. 269 funds tracked by Wall St. Rank hold ARQT as of Q1 2026.

  • Citadel Advisors held 15,606 shares of Arcutis Biotherapeutics worth $368K as of Q1 2026.
  • Citadel Advisors sold 139,552 Arcutis Biotherapeutics shares in Q1 2026, an estimated $3.56M.
  • Arcutis Biotherapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #10004 holding.
  • Citadel Advisors first reported a position in Arcutis Biotherapeutics in Q1 2020 and has held it in 24 quarters since.
  • Citadel Advisors's Arcutis Biotherapeutics position peaked at $28.2M in Q3 2024.
  • 269 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.